NAMS NewAmsterdam Pharma Company NV

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences:

• TD Cowen 45th Annual Healthcare Conference in Boston, MA on Tuesday, March 4 and Wednesday, March 5, 2025. Michael Davidson, M.D., Chief Executive Officer, and Ian Somaiya, Chief Financial Officer, will present a corporate overview at 1:50 p.m. ET on Tuesday, March 4.
• Leerink Partners Global Healthcare Conference 2025 in Miami, FL on Monday, March 10, 2025. Michael Davidson, M.D., Chief Executive Officer, will present a corporate overview at 8:00 a.m. ET.
• Jefferies Biotech on the Beach Summit in Miami, FL on Wednesday, March 12, 2025. Company management will be available for 1x1 meetings throughout the day.

Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.

About NewAmsterdam

NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage, clinical biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.

Company ContactMatthew PhilippeP: 1-917-882-7512matthew.philippe@newamsterdampharma.com

Media ContactSpectrum Science on behalf of NewAmsterdamJaryd LeadyP: 1-856-803-7855jleady@spectrumscience.com

Investor ContactPrecision AQ on behalf of NewAmsterdamAustin MurtaghP: 1-212-698-8696austin.murtagh@precisionaq.com